{"schema_version":"secwatch.filing_event.v1","accession":"0000896622-26-000004","form_type":"8-K","ticker":"ATR","cik":"0000896622","company_name":"APTARGROUP, INC.","filed_at":"2026-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.986754+00:00","generated_at":"2026-05-16T04:44:10.669785+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aptar Q4 net income down 26%, adjusted EPS $1.25 vs $1.62; new $600M buyback","bullets":["Reported sales +14% to $963M (core +5%); net income -26% to $74M ($1.13 EPS).","Adjusted EPS $1.25 vs $1.62; adjusted EBITDA margin 19.8% vs 23.0%.","Pharma core sales +4% (injectables +24%), Beauty +10%, Closures +1%.","Board authorized new $600M share repurchase; Q1 2026 adjusted EPS guidance $1.13-$1.21.","Returned $206M to shareholders in Q4 via buybacks and dividends; quarterly dividend $0.48."],"urls":{"canonical":"https://secwatch.observer/filing/0000896622-26-000004","json":"https://secwatch.observer/filing/0000896622-26-000004.json","markdown":"https://secwatch.observer/filing/0000896622-26-000004.md","text":"https://secwatch.observer/filing/0000896622-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896622/000089662226000004/0000896622-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896622/000089662226000004/atr-20260205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:44:10.669785+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}